Neuralstem delays launch of stem cell trial

02/23/2009 | American City Business Journals

Neuralstem has postponed the start of a Phase I clinical study to test the safety of injecting fetal stem cells into the spinal cords of patients with Lou Gehrig's disease. The move comes after the FDA required the company to revise its proposed protocols for the clinical trial and submit information about its production capabilities and other information. The agency's extensive questions can be addressed "in an expeditious manner," CEO Richard Garr said.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI